Unnamed: 0,title,date,stock,sentiment
1386783.0,"Citigroup Maintains Buy on Acceleron Pharma, Raises Price Target to $137",2020-06-02 09:21:00-04:00,XLRN,neutral
1386784.0,Acceleron Announces Presentations On REBLOZYL (luspatercept-aamt) At 2020 American Society Of Clinical Oncology And European Hematology Association Virtual Annual Meetings,2020-05-20 07:13:00-04:00,XLRN,neutral
1386785.0,Acceleron Highlights Publication In Science Translational Medicine Showing Underlying Biology Behind Sotatercept's Potential As Novel Therapy In Pulmonary Arterial Hypertension,2020-05-13 16:01:00-04:00,XLRN,positive
1386786.0,"The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter",2020-05-13 07:40:00-04:00,XLRN,neutral
1386787.0,Stocks That Hit 52-Week Highs On Tuesday,2020-05-12 10:41:00-04:00,XLRN,neutral
1386788.0,"JP Morgan Maintains Overweight on Acceleron Pharma, Raises Price Target to $118",2020-05-12 10:33:00-04:00,XLRN,neutral
1386789.0,"Oppenheimer Maintains Outperform on Acceleron Pharma, Raises Price Target to $115",2020-05-12 08:08:00-04:00,XLRN,neutral
1386790.0,"The Daily Biotech Pulse: NASH Disappointment For Genfit, Novavax Lands $384M CEPI Funding For Coronavirus Vaccine, GW Pharma Earnings",2020-05-12 08:06:00-04:00,XLRN,negative
1386791.0,"Acceleron Pharma Q1 Net Loss $50.9M, Sales $4.300M Miss $5.260M Estimate",2020-05-11 16:32:00-04:00,XLRN,negative
1386792.0,"The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight",2020-05-10 15:40:00-04:00,XLRN,neutral
1386793.0,"Credit Suisse Maintains Outperform on Acceleron Pharma, Raises Price Target to $123",2020-05-08 10:34:00-04:00,XLRN,positive
1386794.0,"The Daily Biotech Pulse: Ayala IPO, Pluristem Starts Phase 2 Trial Of COVID Treatment, European Nod For Takeda",2020-05-08 07:59:00-04:00,XLRN,neutral
1386795.0,Stocks That Hit 52-Week Highs On Thursday,2020-05-07 10:33:00-04:00,XLRN,neutral
1386796.0,3 Keros Analysts On Why Biopharma Is A Compelling Investment Opportunity,2020-05-04 14:41:00-04:00,XLRN,positive
1386797.0,Acceleron Receives Priority Medicines (PRIME) Designation From European Medicines Agency (EMA) For Sotatercept In Pulmonary Arterial Hypertension,2020-05-04 07:03:00-04:00,XLRN,neutral
1386798.0,Bristol Myers Squibb And Acceleron Receive Positive CHMP Opinion For The Treatment Of Adults With Anemia In Beta Thalassemia And Myelodysplastic Syndromes,2020-04-30 16:27:00-04:00,XLRN,positive
1386799.0,"Shares of several healthcare companies are trading lower with the overall market on continued downward momentum after oil prices fell to historic lows, partially stemming from weak demand caused by the coronavirus pandemic.",2020-04-21 11:35:00-04:00,XLRN,negative
1386800.0,"The Daily Biotech Pulse: Applied DNA Begins Validating COVID-19 Test, Cara's Positive Readout, Novan Explores Strategic Alternatives",2020-04-21 08:19:00-04:00,XLRN,positive
1386801.0,"The Daily Biotech Pulse: Applied DNA Ships Vaccine Constructs For Animal Testing, Herceptin Biosimilar Now Available In US",2020-04-15 08:03:00-04:00,XLRN,neutral
1386802.0,Stocks That Hit 52-Week Highs On Tuesday,2020-04-14 10:31:00-04:00,XLRN,neutral
1386803.0,"The Daily Biotech Pulse: Genmark Pre-Announces Q1 Outperformance, Sage to Eliminate 53% of Workforce, Keros IPO",2020-04-08 07:53:00-04:00,XLRN,neutral
1386804.0,Acceleron Receives FDA Breakthrough Therapy Designation For Sotatercept In Pulmonary Arterial Hypertension,2020-04-08 07:06:00-04:00,XLRN,neutral
1386805.0,"H.C. Wainwright Reiterates Buy on Acceleron Pharma, Raises Price Target to $137",2020-04-07 13:05:00-04:00,XLRN,neutral
1386806.0,"Oppenheimer Maintains Outperform on Acceleron Pharma, Raises Price Target to $112",2020-04-06 10:52:00-04:00,XLRN,neutral
1386807.0,"Benzinga's Top Upgrades, Downgrades For April 6, 2020",2020-04-06 09:31:00-04:00,XLRN,positive
1386808.0,"Goldman Sachs Downgrades Acceleron Pharma to Sell, Announces $73 Price Target",2020-04-06 07:51:00-04:00,XLRN,neutral
1386809.0,Attention Biotech Investors: Mark Your Calendar For These April PDUFA Dates,2020-03-31 17:15:00-04:00,XLRN,neutral
1386810.0,"The Week Ahead In Biotech: Clinical Readouts, COVID-19 News Flow In Focus Amid Continuing Uncertainty",2020-03-29 12:10:00-04:00,XLRN,negative
1386811.0,"The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index",2020-03-10 09:19:00-04:00,XLRN,negative
1386812.0,"H.C. Wainwright Maintains Buy on Acceleron Pharma, Lowers Price Target to $128",2020-03-10 07:35:00-04:00,XLRN,negative
1386813.0,Acceleron Announces ACE-083 Did Not Achieve Statistically Significant Improvements In Functional Endpoints Relative To Placebo; Co. To Discontinue Development of ACE-083,2020-03-09 16:07:00-04:00,XLRN,positive
1386814.0,"The Daily Biotech Pulse: Takeda Jumps Into The COVID-19 Fray, Exact Sciences Buys Cancer Diagnostics Companies",2020-03-04 07:37:00-05:00,XLRN,negative
1386815.0,Stocks That Hit 52-Week Highs On Tuesday,2020-03-03 10:44:00-05:00,XLRN,neutral
1386816.0,"Citigroup Maintains Buy on Acceleron Pharma, Lowers Price Target to $136",2020-03-02 08:12:00-05:00,XLRN,negative
1386817.0,"Acceleron Pharma Q4 EPS $(0.44) Misses $(0.3) Estimate, Sales $39.338M Beat $35.89M Estimate",2020-02-27 16:17:00-05:00,XLRN,negative
1386818.0,"Benzinga's Top Upgrades, Downgrades For February 27, 2020",2020-02-27 09:37:00-05:00,XLRN,positive
1386819.0,"Barclays Initiates Coverage On Acceleron Pharma with Overweight Rating, Announces $107 Price Target",2020-02-27 07:57:00-05:00,XLRN,negative
1386820.0,"The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy",2020-02-27 07:35:00-05:00,XLRN,positive
1386821.0,The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace,2020-02-23 18:38:00-05:00,XLRN,neutral
1386822.0,"H.C. Wainwright Maintains Buy on Acceleron Pharma, Raises Price Target to $129",2020-02-18 07:10:00-05:00,XLRN,neutral
1386823.0,"The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data",2020-02-12 09:18:00-05:00,XLRN,positive
1386824.0,Stocks That Hit 52-Week Highs On Tuesday,2020-02-11 10:17:00-05:00,XLRN,neutral
1386825.0,"Oppenheimer Maintains Outperform on Acceleron Pharma, Raises Price Target to $112",2020-02-11 09:38:00-05:00,XLRN,neutral
1386826.0,"The Daily Biotech Pulse: Assertio To Sell Opioid Pain Drug, Milestone Payment For Aduro, Myriad Genetics CEO Resigns",2020-02-07 07:32:00-05:00,XLRN,negative
1386827.0,"The Daily Biotech Pulse: Merck Spins Off Slow-Growth Businesses, ZioPharm Announces Offering, PhaseBio Data",2020-02-05 07:43:00-05:00,XLRN,neutral
1386828.0,Stocks That Hit 52-Week Highs On Tuesday,2020-02-04 10:18:00-05:00,XLRN,neutral
1386829.0,"The Daily Biotech Pulse: EyePoint In-Licenses Eye Disorder Drug, BioMarin CFO Quits, Rockwell Medical To Offer Shares",2020-02-04 07:51:00-05:00,XLRN,negative
1386830.0,Stocks That Hit 52-Week Highs On Monday,2020-02-03 11:44:00-05:00,XLRN,neutral
1386831.0,"Benzinga's Top Upgrades, Downgrades For February 3, 2020",2020-02-03 09:55:00-05:00,XLRN,positive
1386832.0,Acceleron Pharma shares are trading higher after Morgan Stanley upgraded the stock from Equal-Weight to Overweight and raised the price target from $52 o $122 per share.,2020-02-03 08:44:00-05:00,XLRN,positive
1386833.0,"Morgan Stanley Upgrades Acceleron Pharma to Overweight, Raises Price Target to $122",2020-02-03 05:53:00-05:00,XLRN,negative
1386834.0,"The Week Ahead In Biotech: Merck, Bristol-Myers Earnings, Conference Presentations In Focus",2020-02-02 13:04:00-05:00,XLRN,neutral
1386835.0,Stocks That Hit 52-Week Highs On Friday,2020-01-31 10:23:00-05:00,XLRN,neutral
1386836.0,"The Daily Biotech Pulse: Amgen Hurt By Generic Competition, Nanoviricides Confirms Working On Wuhan Virus, Arcutis IPO",2020-01-31 09:09:00-05:00,XLRN,negative
1386837.0,70 Biggest Movers From Yesterday,2020-01-31 05:24:00-05:00,XLRN,neutral
1386838.0,"The Daily Biotech Pulse: Novartis Earnings, Hepion's NASH Candidate Beats Rival Drugs, Annovis Bio To Debut",2020-01-29 08:30:00-05:00,XLRN,neutral
1386839.0,"Citigroup Maintains Buy on Acceleron Pharma, Raises Price Target to $138",2020-01-29 07:51:00-05:00,XLRN,neutral
1386840.0,70 Biggest Movers From Yesterday,2020-01-29 04:40:00-05:00,XLRN,neutral
1386841.0,Mid-Afternoon Market Update: Dow Surges 250 Points; Delphi Technologies Shares Gain On Acquisition News,2020-01-28 15:00:00-05:00,XLRN,positive
1386842.0,Mid-Day Market Update: Crude Oil Rises Over 1%; Acceleron Pharma Shares Spike Higher,2020-01-28 12:08:00-05:00,XLRN,negative
1386843.0,46 Stocks Moving In Tuesday's Mid-Day Session,2020-01-28 11:50:00-05:00,XLRN,neutral
1386844.0,Stocks That Hit 52-Week Highs On Tuesday,2020-01-28 11:05:00-05:00,XLRN,neutral
1386845.0,Mid-Morning Market Update: Markets Open Higher; Pfizer Earnings Miss Views,2020-01-28 10:22:00-05:00,XLRN,negative
1386846.0,Acceleron Hits All-Time High On Positive Readout For Pulmonary Arterial Hypertension Drug,2020-01-28 09:20:00-05:00,XLRN,positive
1386847.0,10 Biggest Price Target Changes For Tuesday,2020-01-28 08:45:00-05:00,XLRN,neutral
1386848.0,"Piper Sandler Maintains Overweight on Acceleron Pharma, Raises Price Target to $135",2020-01-28 08:32:00-05:00,XLRN,negative
1386849.0,"Goldman Sachs Reiterates Neutral on Acceleron Pharma, Raises Price Target to $81",2020-01-28 08:21:00-05:00,XLRN,neutral
1386850.0,"Credit Suisse Maintains Outperform on Acceleron Pharma, Raises Price Target to $99",2020-01-28 08:08:00-05:00,XLRN,positive
1386851.0,10 Healthcare Stocks Moving In Tuesday's Pre-Market Session,2020-01-28 07:37:00-05:00,XLRN,neutral
1386852.0,6 Biotechnology Stocks Moving In Tuesday's Pre-Market Session,2020-01-28 07:37:00-05:00,XLRN,neutral
1386853.0,24 Stocks Moving in Tuesday's Pre-Market Session,2020-01-28 07:16:00-05:00,XLRN,neutral
1386854.0,"The Daily Biotech Pulse: Acceleron's Positive Data Readout, Surface Oncology Gets Nod For Pushing 2 Antibodies Into Clinics",2020-01-28 07:12:00-05:00,XLRN,positive
1386855.0,"A Peek Into The Markets: US Stock Futures Up Ahead Of Earnings, Fed Meeting",2020-01-28 06:19:00-05:00,XLRN,neutral
1386856.0,Acceleron Pharma shares are trading higher after the company's Sotatercept achieved primary and secondary endpoints in the PULSAR Phase 2 trial in patients with pulmonary arterial hypertension.,2020-01-28 06:11:00-05:00,XLRN,positive
1386857.0,23 Biotechnology Stocks Moving In Monday's After-Market Session,2020-01-27 23:45:00-05:00,XLRN,neutral
1386858.0,36 Healthcare Stocks Moving In Monday's After-Market Session,2020-01-27 23:41:00-05:00,XLRN,neutral
1386859.0,Acceleron Pharma shares are trading higher after the company announced Sotatercept achieved primary and secondary endpoints in PULSAR Phase 2 trial.,2020-01-27 16:05:00-05:00,XLRN,positive
1386860.0,Acceleron Announces Sotatercept Achieved Primary And Secondary Endpoints In PULSAR Phase 2 Placebo-Controlled Trial In Patients With Pulmonary Arterial Hypertension,2020-01-27 16:01:00-05:00,XLRN,neutral
1386861.0,"Citigroup Maintains Buy on Acceleron Pharma, Raises Price Target to $75",2020-01-22 08:12:00-05:00,XLRN,neutral
1386862.0,"The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares",2020-01-17 08:07:00-05:00,XLRN,negative
1386863.0,Stocks That Hit 52-Week Highs On Thursday,2020-01-16 10:22:00-05:00,XLRN,neutral
1386864.0,Stocks That Hit 52-Week Highs On Friday,2020-01-10 12:18:00-05:00,XLRN,neutral
1386865.0,"The Daily Biotech Pulse: Positive Data Readouts To Spur Aclaris, Moderna And Ultragenyx",2020-01-10 07:13:00-05:00,XLRN,positive
1386866.0,Stocks That Hit 52-Week Highs On Thursday,2020-01-09 15:15:00-05:00,XLRN,neutral
1386867.0,Bristol-Myers Squibb Highlights Publishing Of Results For Pivotal Phase 3 Reblozyl MEDALIST Trial In New England Journal Of Medicine,2020-01-09 06:59:00-05:00,XLRN,neutral
1386868.0,Acceleron And Fulcrum Therapeutics Announce Pulmonary Research And Discovery Collaboration Agreement; Fulcrum To Receive $10M Upfront Payment And Milestones Of Up To $295M For First Commercialized Product And Up To $143.5M For Subsequent Products,2019-12-30 07:33:00-05:00,XLRN,positive
1386869.0,Stocks That Hit 52-Week Highs On Friday,2019-12-20 11:59:00-05:00,XLRN,neutral
1386870.0,"The Daily Biotech Pulse: Axovant Surges On Gene Therapy Study Results, FDA Approves Merck's Ebola Vaccine, Abeona Announces Offering",2019-12-20 08:12:00-05:00,XLRN,positive
1386871.0,"The Daily Biotech Pulse: Seattle Genetics' Bladder Cancer Drug Gets FDA Nod, Paratek Wins Contract For Antibiotic",2019-12-19 07:52:00-05:00,XLRN,negative
1386872.0,Stocks That Hit 52-Week Highs On Wednesday,2019-12-18 10:43:00-05:00,XLRN,neutral
1386873.0,"The Daily Biotech Pulse: Positive Adcom Verdict For Merck, Homology Medicine Slips On Mixed Gene Therapy Efficacy Data",2019-12-18 07:23:00-05:00,XLRN,positive
1386874.0,Stocks That Hit 52-Week Highs On Tuesday,2019-12-17 11:19:00-05:00,XLRN,neutral
1386875.0,"Morgan Stanley Maintains Equal-Weight on Acceleron Pharma, Raises Price Target to $52",2019-12-17 08:55:00-05:00,XLRN,neutral
1386876.0,"The Daily Biotech Pulse: Roche Gets US Antitrust Clearance For Spark Purchase, An Orphan Drug Designation For Prevail, Dynavax Names CEO",2019-12-17 07:56:00-05:00,XLRN,positive
1386877.0,"The Daily Biotech Pulse: European Nod For Amgen, miRagen Overhauls Clinical Pipeline, Tonix Snags Patent Win",2019-12-12 07:38:00-05:00,XLRN,positive
1386878.0,Stocks That Hit 52-Week Highs On Wednesday,2019-12-11 10:49:00-05:00,XLRN,neutral
1386879.0,"The Daily Biotech Pulse: Correvio Faces FDA Panel Rejection, Iterum's Antibiotic Trial Narrowly Misses Primary Endpoint",2019-12-11 07:21:00-05:00,XLRN,negative
1386880.0,"The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy $3M In ContraFect Shares",2019-12-10 07:56:00-05:00,XLRN,positive
1386881.0,Bristol-Myers Reports Reblozyl Studies Evaluating Treatment Of Anemia In Rare Blood Diseases Presented At ASH,2019-12-09 16:37:00-05:00,XLRN,neutral
1386882.0,Bristol-Meyers Squibb And Acceleron Were Notified By FDA That Reblozyl Will Not Be Reviewed At Dec. 18 Oncologic Drugs Advisory Committee,2019-12-06 12:07:00-05:00,XLRN,neutral
1386883.0,Bristol-Myers Squibb And Acceleron Pharma Announce FDA Advisory Committee Will Review Reblozyl For Use In Patients With Myelodysplastic Syndromes,2019-12-03 07:40:00-05:00,XLRN,neutral
1386884.0,"The Week Ahead In Biotech: ASH 2019 Gets Underway, Biogen's Aducanumab Data And More",2019-12-01 09:30:00-05:00,XLRN,neutral
1386885.0,60 Biggest Movers From Yesterday,2019-11-07 05:44:00-05:00,XLRN,neutral
1386886.0,62 Stocks Moving In Wednesday's Mid-Day Session,2019-11-06 13:48:00-05:00,XLRN,neutral
1386887.0,"The Daily Biotech Pulse: Sesen Rallies On Positive FDA Meeting, Supernus Flunks Late-Stage ADHD Trial, GW Pharma Earnings",2019-11-06 08:21:00-05:00,XLRN,positive
1386888.0,"Acceleron Pharma Q3 EPS $(0.86) Misses $(0.82) Estimate, Sales $4.21M Miss $4.44M Estimate",2019-11-06 07:54:00-05:00,XLRN,negative
1386889.0,"Morgan Stanley Maintains Equal-Weight on Acceleron Pharma, Lowers Price Target to $48",2019-10-11 08:32:00-04:00,XLRN,negative
1386890.0,"Shares of several healthcare companies are trading lower, potentially on recent Democratic primary polls showing Senator Elizabeth Warren in the lead.",2019-09-26 12:43:00-04:00,XLRN,neutral
1386891.0,Shares of many pharma/therapeutics stocks trading lower in sympathy with overall market weakness. Reports China is planning to cut prices for widely-used drugs may also be pressuring the sector today.,2019-09-24 14:01:00-04:00,XLRN,negative
1386892.0,10 Biggest Price Target Changes For Tuesday,2019-09-17 08:23:00-04:00,XLRN,neutral
1386893.0,25 Stocks Moving in Tuesday's Pre-Market Session,2019-09-17 07:42:00-04:00,XLRN,neutral
1386894.0,"Citi Maintains Buy on Acceleron Pharma, Lowers Price Target to $52",2019-09-17 07:39:00-04:00,XLRN,negative
1386895.0,"The Daily Biotech Pulse: Acceleron Shelves Muscular Dystrophy Drug Trial, Aclaris Aces Late-Stage Study",2019-09-17 07:23:00-04:00,XLRN,neutral
1386896.0,"Citigroup Maintains Buy on Acceleron Pharma, Lowers Price Target to $52",2019-09-17 07:07:00-04:00,XLRN,negative
1386897.0,Acceleration Pharma shares are trading lower after the company reported that its topline results from the Phase 2 trial of ACE-083 did not receive statistically significant improvements in functional endpoints.,2019-09-16 16:35:00-04:00,XLRN,positive
1386898.0,Acceleron Reports Topline Results From Phase 2 Trial Of ACE-083 In Patients With Facioscapulohumeral Muscular Dystrophy: Did Not Achieve Statistically Significant Improvements In Functional Endpoints,2019-09-16 16:31:00-04:00,XLRN,positive
1386899.0,Acceleron's Pulmonary Arterial Hypertension Asset Receives Orphan Drug Designation,2019-09-09 11:15:00-04:00,XLRN,positive
1386900.0,Acceleron Receives FDA Orphan Drug Designation for Sotatercept in Pulmonary Arterial Hypertension,2019-09-09 07:04:00-04:00,XLRN,neutral
1386901.0,"JP Morgan Maintains Overweight on Acceleron Pharma, Lowers Price Target to $58",2019-08-06 08:15:00-04:00,XLRN,negative
1386902.0,"Acceleron Pharma Q2 EPS $(0.34) Misses $(0.29) Estimate, Sales $27.666M Beat $26.64M Estimate",2019-08-05 16:20:00-04:00,XLRN,negative
1386903.0,"The Week Ahead In Biotech: Focus On Earnings Deluge, Mid-Year Clinical Trial Readouts",2019-08-03 10:18:00-04:00,XLRN,neutral
1386904.0,Shares of several drug manufacturing companies are trading lower. The Trump Administration earlier rolled back a proposal to eliminate rebates from government drug plans and commented on continued efforts to lower drug prices.,2019-07-11 10:36:00-04:00,XLRN,negative
1386905.0,"Shares of several healthcare companies are trading lower after Trump on Friday said he was preparing an executive order declaring a 'favored nations clause' for drug prices, lowering the price that consumers will pay prescription drugs.",2019-07-08 12:55:00-04:00,XLRN,positive
1386906.0,Acceleron Completes Target Enrollment In PULSAR Phase 2 Trial Of Sotatercept In Pulmonary Arterial Hypertension,2019-06-26 07:36:00-04:00,XLRN,neutral
1386907.0,Acceleron Pharma Reports Co-Founder Tom Maniatis To Retire,2019-06-10 07:03:00-04:00,XLRN,neutral
1386908.0,"Celgene, Acceleron Pharma Report FDA Acceptance Of Luspatercept Biologics License Application In Myelodysplastic Syndromes, Beta-Thalassemia",2019-06-04 07:32:00-04:00,XLRN,positive
1386909.0,5 Small-Cap Biotechs In Citi's Buy List With Big Upside Potential,2019-05-29 12:24:00-04:00,XLRN,neutral
1386910.0,"Goldman Sachs Assumes Acceleron Pharma at Neutral, Announces Price Target $54",2019-05-29 07:34:00-04:00,XLRN,neutral
1386911.0,Citigroup Assumes Acceleron Pharma Inc. - Common Stock at Buy,2019-05-24 10:06:00-04:00,XLRN,neutral
1386912.0,"Acceleron Pharma Q1 EPS $(0.74) Misses $(0.59) Estimate, Sales $2.78M Miss $7.32M Estimate",2019-05-09 17:07:00-04:00,XLRN,negative
1386913.0,"The Daily Biotech Pulse: Novartis Goes Shopping, Mixed Trial Results For Provention Bio, 4 Stocks To Debut",2019-05-09 07:56:00-04:00,XLRN,neutral
1386914.0,"Barclays Downgrades Acceleron Pharma Inc. - Common Stock to Equal-Weight, Lowers Price Target to $45",2019-05-03 08:44:00-04:00,XLRN,negative
1386915.0,Shares of several healthcare companies are trading lower on continued uncertainty over healthcare policy as well as concerns over the medicare-for-all proposals among 2020 candidates.,2019-04-30 12:16:00-04:00,XLRN,negative
1386916.0,Celgene Corporation And Acceleron Pharma Announce Submission Of Luspatercept Marketing Authorization Application To European Medicines Agency For MDS And Beta-Thalassemia,2019-04-26 07:37:00-04:00,XLRN,neutral
1386917.0,Oppenheimer Assumes Acceleron Pharma at Outperform,2019-04-22 10:21:00-04:00,XLRN,neutral
1386918.0,"Geron's Blood Cancer Candidate Creates Buying Opportunity, Needham Says In Upgrade",2019-04-09 14:50:00-04:00,XLRN,negative
1386919.0,"Celgene, Acceleron Reports Submission Of Luspatercept Biologics License Application To FDA",2019-04-05 09:28:00-04:00,XLRN,neutral
1386920.0,"The Daily Biotech Pulse: Merrimack Pulls The Plug On Early-Stage Trial, Legal Headache For Novartis-Amgen Migraine Partnership",2019-04-05 07:48:00-04:00,XLRN,positive
1386921.0,Acceleron Discontinues Development Of Phase 1 Molecule Ace-2494; Frequency Of Anti-Drug Antibodies Observed Among Participants In Study Has Led Co To Discontinue The Program,2019-04-04 16:08:00-04:00,XLRN,neutral
1386922.0,Acceleron Receives FDA Orphan Drug Designation For ACE-083 In Charcot-Marie-Tooth Disease,2019-03-05 07:12:00-05:00,XLRN,neutral
1386923.0,"Acceleron Pharma Q4 EPS $(0.75) Misses $(0.68) Estimate, Sales $3.82M Beat $3.12M Estimate",2019-02-27 16:40:00-05:00,XLRN,negative
1386924.0,"Cowen & Co. Initiates Coverage On Acceleron Pharma with Outperform Rating, Announces $78 Price Target",2019-02-26 06:42:00-05:00,XLRN,neutral
1386925.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs",2019-02-22 13:55:00-05:00,XLRN,neutral
1386926.0,35 Stocks Moving In Friday's Pre-Market Session,2019-02-01 08:33:00-05:00,XLRN,neutral
1386927.0,Acceleron Prices ~5.35M Share Common Stock Offering At $43/Share,2019-01-16 07:02:00-05:00,XLRN,positive
1386928.0,55 Biggest Movers From Yesterday,2019-01-16 05:12:00-05:00,XLRN,neutral
1386929.0,40 Stocks Moving In Tuesday's Mid-Day Session,2019-01-15 12:36:00-05:00,XLRN,neutral
1386930.0,Acceleron Pharma shares are trading higher after the company reported a $200 million common stock offering.,2019-01-15 10:58:00-05:00,XLRN,positive
1386931.0,24 Stocks Moving In Tuesday's Pre-Market Session,2019-01-15 08:00:00-05:00,XLRN,neutral
1386932.0,"10 Stocks To Watch For January 15, 2019",2019-01-15 04:30:00-05:00,XLRN,neutral
1386933.0,Acceleron Pharma shares are trading lower after the company announced a proposed $200 million common stock offering.,2019-01-14 17:24:00-05:00,XLRN,neutral
1386934.0,Acceleron Reports $200M Common Stock Offering,2019-01-14 16:04:00-05:00,XLRN,neutral
1386935.0,Acceleron Highlights Publication Of Luspatercept Phase 2 Beta-Thalassemia Study Results In Blood,2019-01-10 07:08:00-05:00,XLRN,neutral
1386936.0,24 Stocks Moving In Tuesday's Pre-Market Session,2019-01-08 08:19:00-05:00,XLRN,neutral
1386937.0,"Celgene, Acceleron Announce Phase 3 MEDALIST Trial Evaluating Luspatercept in Patients with Myelodysplastic Syndromes Presented at ASH 2018 Met The Primary Endpoint Of Red Blood Cell Transfusion Independence (RBC-TI) For 8 Or More Weeks During The First 24 Weeks Of The Study.",2018-12-02 18:25:00-05:00,XLRN,neutral
1386938.0,"The Week Ahead In Biotech: ASH Presentations Pick Up Pace, PDUFA Dates, Clinical Trials And IPOs",2018-12-02 17:51:00-05:00,XLRN,neutral
1386939.0,"Celgene, Acceleron Announce Phase 3 BELIEVE Trial Evaluating Luspatercept in Adult Patients with Beta-Thalassemia Met Primary Endpoint of Erythroid Response at ASH 2018",2018-12-02 10:12:00-05:00,XLRN,neutral
1386940.0,Acceleron Pharma Reports Fast Track Designation For ACE-083 For Charcot-Marie-Tooth Disease,2018-11-28 07:05:00-05:00,XLRN,neutral
1386941.0,"The Week Ahead In Biotech: ASH 2018, PDUFA Dates, Clinical Trials And Earnings",2018-11-25 09:41:00-05:00,XLRN,neutral
1386942.0,Acceleron Announces To Present Phase 3 Results From MEDALIST And BELIEVE Trials Of Luspatercept At 60th American Society Of Hematology Annual Meeting Dec 1-4,2018-11-01 09:09:00-04:00,XLRN,neutral
1386943.0,"Acceleron Q3 EPS $(0.63) Beats $(0.66) Estimate, Sales $3.258M Miss $3.9M Estimate",2018-10-30 17:02:00-04:00,XLRN,negative
1386944.0,"The Daily Biotech Pulse: Pfizer And Allergan Earnings, CFO Departures At Acadia And Assertio",2018-10-30 08:00:00-04:00,XLRN,neutral
1386945.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results, Earnings And IPOs",2018-10-27 10:23:00-04:00,XLRN,neutral
1386946.0,"The Daily Biotech Pulse: MediciNova Gets Orphan-Drug Status, KemPharm To Offer Shares, Emergent Buys Vaccine Maker",2018-10-05 08:35:00-04:00,XLRN,positive
1386947.0,"Stocks Which Set New 52-Week High Friday, September 21",2018-09-24 09:43:00-04:00,XLRN,neutral
1386948.0,"The Daily Biotech Pulse: Exelixis Liver Cancer Drug On Track For European Approval, Medtronic Goes Shopping, Opiant Snags BARDA Funding",2018-09-21 08:51:00-04:00,XLRN,negative
1386949.0,"Stocks Which Set New 52-Week High Yesterday, September 20th",2018-09-21 08:16:00-04:00,XLRN,neutral
1386950.0,"Stocks Which Set New 52-Week High Yesterday, September 19th",2018-09-20 11:24:00-04:00,XLRN,neutral
1386951.0,"The Daily Biotech Pulse: Adverum Snags Fast Track Designation, Crispr To Offer Shares, Elanco Animal Health To Debut",2018-09-20 09:02:00-04:00,XLRN,positive
1386952.0,Analyst: Acceleron's Blood Disorder Candidate Luspatercept Has Blockbuster Potential,2018-09-18 14:44:00-04:00,XLRN,positive
1386953.0,10 Biggest Price Target Changes For Tuesday,2018-09-18 10:23:00-04:00,XLRN,neutral
1386954.0,"Benzinga's Top Upgrades, Downgrades For September 18, 2018",2018-09-18 09:10:00-04:00,XLRN,positive
1386955.0,"PiperJaffray Upgrades Acceleron Pharma to Overweight, Raises Price Target to $75",2018-09-18 06:39:00-04:00,XLRN,negative
1386956.0,"Morgan Stanley Assumes Acceleron Pharma at Equal-Weight, Announces Price Target $55",2018-09-10 07:28:00-04:00,XLRN,neutral
1386957.0,"Stocks Which Set New 52-Week High Friday, August 31",2018-09-04 10:29:00-04:00,XLRN,neutral
1386958.0,"Stocks Which Set New 52-Week High Yesterday, August 30th",2018-08-31 10:11:00-04:00,XLRN,neutral
1386959.0,"The Daily Biotech Pulse: FDA Blessings for Merck's HIV Drug Combo, Veracyte's Test Gets Medicare Coverage",2018-08-31 08:29:00-04:00,XLRN,positive
1386960.0,"Stocks Which Set New 52-Week High Yesterday, August 29th",2018-08-30 11:47:00-04:00,XLRN,neutral
1386961.0,"The Daily Biotech Pulse: Verastem Gets New CFO, Mesoblast Earnings, Vertex's Precision Medicine Collaboration",2018-08-30 08:02:00-04:00,XLRN,neutral
1386962.0,"Stocks Which Set New 52-Week High Yesterday, August 28th",2018-08-29 11:13:00-04:00,XLRN,neutral
1386963.0,"Stocks Which Set New 52-Week High Friday, August 24th",2018-08-27 09:24:00-04:00,XLRN,neutral
1386964.0,"13F From Omega Shows Exited Stake In Acceleron Pharma, Xencor and Shell Midstream Partners",2018-08-14 11:27:00-04:00,XLRN,neutral
1386965.0,"The Daily Biotech Pulse: Zafgen Executive Departs; Adamas, Acceleron Accelerate On Earnings",2018-08-03 07:52:00-04:00,XLRN,neutral
1386966.0,"Acceleron Pharma Q2 EPS $(0.63) Beats $(0.64) Estimate, Sales $3.69M Miss $3.8M Estimate",2018-08-02 17:10:00-04:00,XLRN,negative
1386967.0,"The Daily Biotech Pulse: Denali's Parkinson's Candidate Clears Early-Stage Trials, Dexcom's Strong Quarter",2018-08-02 08:54:00-04:00,XLRN,positive
1386968.0,Acceleron Pharma Q2 Earnings Preview,2018-08-02 07:53:00-04:00,XLRN,neutral
1386969.0,Acceleron Pharma Option Alert: Aug 17 $50 Calls at the Ask: 3000 @ $0.201 vs 3933 OI; Earnings 8/2 After Close Ref=$42.0,2018-07-31 09:42:00-04:00,XLRN,positive
1386970.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs",2018-07-28 14:04:00-04:00,XLRN,neutral
1386971.0,Acceleron Announces Preliminary Results from Part 1 of the ACE-083 Phase 2 Trial in Patients with Charcot-Marie-Tooth Disease,2018-07-23 07:03:00-04:00,XLRN,neutral
1386972.0,Morgan Stanley Downgrades Acceleron As Valuation Reaches Price Target,2018-07-13 12:45:00-04:00,XLRN,positive
1386973.0,"Benzinga's Top Upgrades, Downgrades For July 13, 2018",2018-07-13 09:05:00-04:00,XLRN,positive
1386974.0,Morgan Stanley Downgrades Acceleron Pharma to Equal-Weight,2018-07-13 07:11:00-04:00,XLRN,neutral
1386975.0,Acceleron Receives FDA Orphan Drug Designation for ACE-083 in Facioscapulohumeral Muscular Dystrophy,2018-07-12 07:02:00-04:00,XLRN,neutral
1386976.0,PiperJaffray Downgrades Acceleron Pharma to Neutral,2018-07-10 08:57:00-04:00,XLRN,neutral
1386977.0,"Benzinga's Daily Biotech Pulse: Acceleron On Fast Lane, OncoCyte's Accurate Diagnosis, Inspire Medical Gets Aetna Coverage",2018-07-10 08:11:00-04:00,XLRN,positive
1386978.0,20 Stocks Moving In Tuesday's Pre-Market Session,2018-07-10 08:01:00-04:00,XLRN,neutral
1386979.0,Acceleron Pharma Shares Up 11.6% After Co. Achieved Primary And All Key Secondary Endpoints In Phase III 'BELIEVE' Study Of Luspatercept With Celgene,2018-07-09 17:32:00-04:00,XLRN,positive
1386980.0,Celgene And Acceleron Announce Luspatercept Achieved Primary And All Key Secondary Endpoints In Phase III 'BELIEVE' Study In Adults With Transfusion-Dependent Beta-Thalassemia; Regulatory Submissions Planned In US And Europe In 1H 2019,2018-07-09 16:54:00-04:00,XLRN,neutral
1386981.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials",2018-07-08 19:16:00-04:00,XLRN,neutral
1386982.0,Acceleron Pharma Names Robert Zeldin Chief Medical Officer,2018-07-05 16:30:00-04:00,XLRN,neutral
1386983.0,44 Biggest Movers From Friday,2018-07-02 04:48:00-04:00,XLRN,neutral
1386984.0,Mid-Afternoon Market Update: Echelon Climbs On Acquisition News; InspireMD Shares Slide,2018-06-29 14:25:00-04:00,XLRN,positive
1386985.0,35 Stocks Moving In Friday's Mid-Day Session,2018-06-29 12:18:00-04:00,XLRN,neutral
1386986.0,Mid-Day Market Update: Crude Oil Up Over 1%; Gemphire Therapeutics Shares Spike Higher,2018-06-29 12:04:00-04:00,XLRN,negative
1386987.0,"Acceleron Pharma Rallies After Phase 3 MDS Data, But Goldman Sachs Still Isn't Buying",2018-06-29 11:10:00-04:00,XLRN,neutral
1386988.0,'The success of $XLRN luspatercept is bad for $GERN and another reason for $JNJ to sever the imetelstat relationship in Q3.'-STAT's Adam Feuerstein Tweets,2018-06-29 10:01:00-04:00,XLRN,positive
1386989.0,10 Biggest Price Target Changes For Friday,2018-06-29 09:38:00-04:00,XLRN,neutral
1386990.0,"Benzinga's Top Upgrades, Downgrades For June 29, 2018",2018-06-29 09:19:00-04:00,XLRN,positive
1386991.0,"Benzinga's Daily Biotech Pulse: Gemphire On Fire, Acceleron-Celgene Taste Success, AbbVie Ditches Galapagos",2018-06-29 08:11:00-04:00,XLRN,positive
1386992.0,"Goldman Sachs Upgrades Acceleron Pharma to Neutral, Raises Price Target to $40",2018-06-29 07:52:00-04:00,XLRN,neutral
1386993.0,"Celgene, Acceleron Announce Luspatercept Achieved Primary and Key Secondary Endpoints in Phase III 'MEDALIST' Study",2018-06-28 16:34:00-04:00,XLRN,neutral
1386994.0,Acceleron To Present Preliminary Data On ACE-083 At 2018 Annual Meeting Of The Peripheral Nerve Society July 22-25,2018-06-26 07:05:00-04:00,XLRN,neutral
1386995.0,"UPDATE: Acceleron Says Of Transfusion-Dependent Patients, '41% (12 of 29) achieved a reduction in RBC transfusion burden of at least 33% in the fixed 12-week intervals including weeks 13-24, 37-48 when compared to baseline'",2018-06-15 07:07:00-04:00,XLRN,negative
1386996.0,"UPDATE: Acceleron On Luspatercept Results: 'At week 48, the mean improvement in 6-minute walk distance was 18.6% compared to baseline'",2018-06-15 07:06:00-04:00,XLRN,positive
1386997.0,"Acceleron Offers Updated Results From Ongoing Phase 2 Trials Of Luspatercept In Patients With Beta-Thalassemia, Showed 51% (16 Of 30) Patients Achieved ≥ 1 gram per deciliter increase in hemoglobin in the fixed 12-week intervals including weeks 13-24'",2018-06-15 07:06:00-04:00,XLRN,positive
1386998.0,Accleron Option Alert: Aug 17 $45 Calls at the Ask: 800 @ $5.201 vs 1205 OI; Earnings 8/2 After Close [est] Ref=$36.71,2018-06-05 11:01:00-04:00,XLRN,positive
1386999.0,Acceleron Announces Updated Results from Ongoing Phase 2 Trials of Luspatercept in Myelodysplastic Syndromes at the ASCO 2018 Annual Meeting,2018-06-04 07:05:00-04:00,XLRN,neutral
1387000.0,The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines,2018-06-03 19:27:00-04:00,XLRN,negative
1387001.0,"UBS Global Healthcare Conference 2018 Continues Today, Presenters Include: Civitas Solutions, Revance, Akebia Therapeutics, Bristol-Myers, Senseonics, Lantheus, Acceleron Pharma, and HCA Healthcare",2018-05-22 07:05:00-04:00,XLRN,positive
1387002.0,Acceleron Announces Initiation Of PULSAR Phase 2 Trial Of Sotatercept In Pulmonary Arterial Hypertension,2018-05-22 07:01:00-04:00,XLRN,neutral
1387003.0,"SMid-Cap Biotech: Barclays Downgrades Prothena, Upgrades Achillion",2018-05-21 13:56:00-04:00,XLRN,neutral
1387004.0,"Acceleron Pharma Q1 EPS $(0.58) Beats $(0.64) Estimate, Sales $3.232M Miss $4.21M Estimate",2018-05-08 17:21:00-04:00,XLRN,negative
1387005.0,"Benzinga's Daily Biotech Pulse: Valeant Earnings, Lipocine's FDA Watch, Invivo CFO Departure",2018-05-08 07:55:00-04:00,XLRN,neutral
1387006.0,Acceleron Receives FDA Fast Track Designation for ACE-083 in Facioscapulohumeral Muscular Dystrophy,2018-05-01 08:10:00-04:00,XLRN,neutral
1387007.0,"Citigroup Maintains Buy on Acceleron Pharma, Raises Price Target to $63.00",2018-03-01 08:44:00-05:00,XLRN,neutral
1387008.0,"Barclays Maintains Overweight on Acceleron Pharma, Raises Price Target to $54.00",2018-02-28 11:44:00-05:00,XLRN,negative
1387009.0,"Acceleron Reports Publication Of ACE-083 Phase I Trial Results In Journal 'Muscle & Nerve': 'treatment generated dose-dependent mean total muscle volume increases of up to 14.5% in the RF, 8.9% in the TA three weeks after last dose'",2018-02-28 07:11:00-05:00,XLRN,neutral
1387010.0,"Acceleron Reports Q4 EPS $(0.62) vs $(0.51) In Same Qtr. Last Year, Sales $3.705M",2018-02-27 16:48:00-05:00,XLRN,neutral
1387011.0,38 Biggest Movers From Yesterday,2018-02-27 04:58:00-05:00,XLRN,neutral
1387012.0,28 Stocks Moving In Monday's Mid-Day Session,2018-02-26 12:25:00-05:00,XLRN,neutral
1387013.0,"Benzinga's Top Upgrades, Downgrades For February 26, 2018",2018-02-26 09:51:00-05:00,XLRN,positive
1387014.0,JP Morgan Upgrades Acceleron Pharma to Overweight,2018-02-26 07:58:00-05:00,XLRN,neutral
1387015.0,"The Week Ahead In Biotech: Earnings, PDUFA Dates And More",2018-02-25 15:50:00-05:00,XLRN,neutral
1387016.0,UPDATE: Acceleron Says Co. Planning To Initiate Part 2 Of FSHD Phase 2 Trial In Q2'18,2018-01-08 11:06:00-05:00,XLRN,neutral
1387017.0,UPDATE: Acceleron Says 'Mean total muscle volume increases of over 12% in the tibialis anterior and biceps brachii muscle cohorts',2018-01-08 11:05:00-05:00,XLRN,neutral
1387018.0,Acceleron Pharma Reports Prelim. Results From Part 1 Of ACE-083 Phase 2 Trial In Patients With Facioscapulohumeral Dystrophy,2018-01-08 11:05:00-05:00,XLRN,neutral
1387019.0,"Acceleron Announces Prelim Results For Phase 2 Trial Of ACE-083 Demonstrate Positive Safety Profile, Co. Will Initiate Part 2 Of Trial In Q2",2018-01-08 09:12:00-05:00,XLRN,positive
1387020.0,"Acceleron Announces Planned Retirement of Chief Medical Officer, Dr. Matthew L. Sherman",2018-01-03 07:02:00-05:00,XLRN,neutral
1387021.0,Acceleron Announces Updated Results from Ongoing Phase 2 Trials of Luspatercept in Myelodysplastic Syndromes at #ASH2017,2017-12-10 15:20:00-05:00,XLRN,neutral
1387022.0,"REMINDER: ASH Meeting Begins Tomorrow Dec. 9, Presenters Include Bellicum Pharmaceuticals, Affimed, Cellectis (Pediatric Data for UCART19), and Acceleron Pharma",2017-12-08 15:03:00-05:00,XLRN,neutral
1387023.0,Acceleron Announces Preclinical Results For TGF-beta Therapy,2017-11-14 17:13:00-05:00,XLRN,neutral
1387024.0,"13F Filing From Baker Bros Shows Increased Stake In Acceleron Pharma, New Stake In Acorda Therapeutics",2017-11-14 15:51:00-05:00,XLRN,positive
1387025.0,"Credit Suisse Maintains Outperform on Acceleron Pharma, Raises Price Target to $51.00",2017-11-14 08:42:00-05:00,XLRN,positive
1387026.0,"Acceleron Pharma Reports Q3 EPS $(0.65) vs $(0.64) Est., Sales $3.01M vs $4.8M Est.",2017-11-07 07:26:00-05:00,XLRN,neutral
1387027.0,"4 Biotech Stocks Initiated At Buy: Acceleron, Tesaro, Mirati, Fate",2017-10-12 15:32:00-04:00,XLRN,neutral
1387028.0,"Benzinga's Top Upgrades, Downgrades For October 12, 2017",2017-10-12 09:14:00-04:00,XLRN,positive
1387029.0,"H.C. Wainwright Initiates Coverage On Acceleron Pharma with Buy Rating, Announces $57.00 Price Target",2017-10-12 07:03:00-04:00,XLRN,neutral
1387030.0,Mid-Afternoon Market Update: Scholastic Falls After Q1 Results; Akari Therapeutics Shares Surge,2017-09-21 14:50:00-04:00,XLRN,positive
1387031.0,12 Biggest Mid-Day Losers For Thursday,2017-09-21 12:52:00-04:00,XLRN,negative
1387032.0,Acceleron Reports Offering Of $150M In Common Stock,2017-09-19 16:13:00-04:00,XLRN,neutral
1387033.0,"Acceleron Pharma and Celgene Enter Into Amended Collaboration, License and Option Agreement Originally Dated Feb 20, 2008",2017-09-19 07:03:00-04:00,XLRN,positive
1387034.0,RBC Initiated Coverage On 33 Pharma/Biotech Cos.,2017-09-15 07:38:00-04:00,XLRN,neutral
1387035.0,"Acceleron Pharma Reports Q2 EPS $(0.77) vs $(0.63) Est., Sales $3.05M vs $3.69M Est.",2017-08-03 16:48:00-04:00,XLRN,neutral
1387036.0,Acceleron Announces First Patient Treated in Phase 2 Clinical Trial of ACE-083 in Charcot-Marie-Tooth Disease,2017-08-01 07:07:00-04:00,XLRN,neutral
1387037.0,Acceleron Provides Updated Results from Ongoing Phase 2 Study of Luspatercept in Myelodysplastic Syndromes #EHA2017,2017-06-23 04:24:00-04:00,XLRN,neutral
1387038.0,Acceleron Provides Updated Results from Phase 2 Studies of Luspatercept in Beta-Thalassemia #EHA2017,2017-06-23 04:23:00-04:00,XLRN,neutral
1387040.0,"Benzinga's Top Upgrades, Downgrades For June 13, 2017",2017-06-13 09:55:00-04:00,XLRN,positive
1387041.0,25 Stocks Moving In Tuesday's Pre-Market Session,2017-06-13 08:10:00-04:00,XLRN,neutral
1387042.0,Oppenheimer Downgrades Acceleron Pharma to Market Perform,2017-06-13 07:15:00-04:00,XLRN,neutral
1387043.0,UPDATE: Acceleron Announces Will Discontinue Development Of Dalantercept,2017-06-12 16:35:00-04:00,XLRN,neutral
1387044.0,Acceleron Offers Results From DART Phase 2 Study Of Dalantercept In Advanced Renal Cell Carcinoma: Did Not Achieve Primary Endpoint,2017-06-12 16:34:00-04:00,XLRN,positive
1387045.0,"Benzinga's Top Upgrades, Downgrades For May 17, 2017",2017-05-17 09:25:00-04:00,XLRN,positive
1387046.0,"Goldman Sachs Initiates Coverage On Acceleron Pharma with Sell Rating, Announces $20.00 Price Target",2017-05-17 07:04:00-04:00,XLRN,neutral
1387047.0,"Acceleron Pharma Q1 EPS $(0.66) vs $(0.54) Est, Sales $3.71M vs $3.91M Est",2017-05-08 07:16:00-04:00,XLRN,neutral
1387048.0,Acceleron Pharma Reports Steven Ertel To Transition From COO To Special Advisor To The CEO,2017-05-02 16:38:00-04:00,XLRN,positive
1387049.0,"UPDATE: Acceleron Announces Co., Celgene Will Initiate Added Phase 3 Trial in MDS in Early '18",2017-04-27 07:53:00-04:00,XLRN,neutral
1387050.0,Acceleron Announces 'Enrollment in MEDALIST and BELIEVE Phase 3 studies now expected to be completed in Q2 2017',2017-04-27 07:52:00-04:00,XLRN,neutral
1387051.0,UPDATE: Acceleron Says Second Phase 2 Study for ACE-083 Expected to Begin 2H'17,2017-03-16 07:02:00-04:00,XLRN,neutral
1387052.0,Acceleron Pharma Reports Plan to Initiate Phase 2 Trial of ACE-083 in Charcot-Marie-Tooth Neuromuscular Disease,2017-03-16 07:01:00-04:00,XLRN,neutral
1387053.0,"Benzinga's Top Upgrades, Downgrades For March 14, 2017",2017-03-14 09:32:00-04:00,XLRN,positive
1387054.0,"JP Morgan Initiates Coverage On Acceleron Pharma With Neutral, Announces $33 Price Target",2017-03-14 06:26:00-04:00,XLRN,positive
1387055.0,"UBS Initiates Coverage On Acceleron Pharma With Buy, Announces $36 Price Target",2017-03-09 06:17:00-05:00,XLRN,neutral
1387056.0,25 Biggest Mid-Day Gainers For Thursday,2017-03-02 12:39:00-05:00,XLRN,neutral
1387057.0,"Benzinga's Top Upgrades, Downgrades For March 2, 2017",2017-03-02 09:36:00-05:00,XLRN,positive
1387058.0,Nomura Initiates Coverage On Acceleron Pharma at Buy,2017-03-02 07:33:00-05:00,XLRN,neutral
1387059.0,"Citigroup Upgrades Acceleron Pharma to Buy, Lowers Price Target to $36.00",2017-03-02 07:17:00-05:00,XLRN,negative
1387060.0,"Acceleron Reports Q4 EPS $(0.51) vs $(0.55) Est., Sales $3.369M vs $3.7M Est.",2017-03-01 07:30:00-05:00,XLRN,neutral
1387061.0,TheStreet's Adam Feuerstein Tweets '$CELG spending a lot of time talking up pipeline from partners. $BLUE $XLRN etc. #JPM17',2017-01-09 10:54:00-05:00,XLRN,neutral
1387062.0,Acceleron Outlines 2017 Timeline,2017-01-06 07:05:00-05:00,XLRN,neutral
1387063.0,Oppenheimer Earlier Initiated Coverage On Acceleron Pharma at Outperform,2016-12-13 09:56:00-05:00,XLRN,neutral
1387064.0,What Is The ASH Conference And Why Should Biotech Investors Care?,2016-12-05 12:16:00-05:00,XLRN,positive
1387065.0,"Acceleron, Celgene Announce Updated Results from Ongoing Phase 2 Studies of Luspatercept in Myelodysplastic Syndromes at ASH 2016",2016-12-04 17:40:00-05:00,XLRN,neutral
1387066.0,"American Society Of Hematology Meeting Begins Dec. 3rd, Day 1 of 4",2016-12-02 10:53:00-05:00,XLRN,neutral
1387067.0,"Acceleron Pharma Block Of 450K Shares Trading At UBS, Price $38.50",2016-11-17 14:09:00-05:00,XLRN,negative
1387068.0,"Acceleron Pharma Reports Q3 EPS $(0.55) vs. Est. $(0.53), Rev. $3.005M vs. $4.08M",2016-11-03 17:35:00-04:00,XLRN,neutral
1387069.0,"Citigroup Initiates Coverage on Acceleron Pharma at Neutral, Announces $40.00 PT",2016-09-29 06:11:00-04:00,XLRN,neutral
1387070.0,"Acceleron Announces John Knopf To Retire As CEO, Habib Dable Named Successor Effective Dec 1",2016-09-27 16:01:00-04:00,XLRN,positive
1387071.0,20 Stocks Which Rallied Three Days,2016-09-15 11:05:00-04:00,XLRN,neutral
1387072.0,Benzinga's Top Initiations,2016-08-19 09:16:00-04:00,XLRN,positive
1387073.0,Acceleron Has 2 Phase III Trials With Good Chance Of Success; BTIG Initiates Stock At Buy,2016-08-19 09:11:00-04:00,XLRN,positive
1387074.0,"BTIG Research Initiates Coverage on Acceleron Pharma at Buy, Announces $46.00 PT",2016-08-19 07:56:00-04:00,XLRN,neutral
1387075.0,"Acceleron Pharma Reports Q2 EPS $(0.59) vs. Est. $(0.50), Rev. $3.195M vs. Est. $3.77M",2016-08-04 07:05:00-04:00,XLRN,neutral
1387076.0,Acceleron Reports ACE-083 Phase 1 Results at the 14th International Congress on Neuromuscular Diseases,2016-07-08 07:01:00-04:00,XLRN,neutral
1387077.0,Analysts Confident In Acceleron Pharma's Drug Trial Outcomes,2016-06-23 13:30:00-04:00,XLRN,positive
1387078.0,"Acceleron's Luspatercept Is All About Duration, And This Analyst Is Excited About Its Prospects",2016-06-13 16:38:00-04:00,XLRN,positive
1387079.0,Barclays Raises Acceleron Price Target On Positive Luspatercept Data,2016-06-13 10:10:00-04:00,XLRN,positive
1387080.0,"Acceleron, Celgene Offer Updated Results from Ongoing Phase 2 Study of Luspatercept",2016-06-10 07:02:00-04:00,XLRN,neutral
1387081.0,"Acceleron Reports Q1 EPS $0.13 vs $(0.45) in Same Qtr. Last Year, Sales $18.2M",2016-05-05 07:29:00-04:00,XLRN,neutral
1387082.0,"Barclays Initiates Coverage on Acceleron Pharma at Overweight, Announces $40.00 PT",2016-04-27 06:13:00-04:00,XLRN,negative
1387083.0,Janney: Time To Buy Acceleron,2016-02-29 12:52:00-05:00,XLRN,neutral
1387084.0,Benzinga's Top Upgrades,2016-02-29 08:51:00-05:00,XLRN,positive
1387085.0,Janney Capital Upgrades Acceleron Pharma to Buy,2016-02-29 06:29:00-05:00,XLRN,neutral
1387086.0,"Acceleron Pharma Reports Q4 EPS $(0.81) vs $(0.55) in Same Qtr. Last Year, Sales $3.804M vs $3.739M YoY",2016-02-25 07:29:00-05:00,XLRN,neutral
1387087.0,"Acceleron Pharma Reports Q4 EPS $(0.81) vs $(0.55) in Same Qtr. Last Year, Sales $3.804M vs $3.739M YoY",2016-02-25 07:26:00-05:00,XLRN,neutral
1387088.0,Oppenheimer Assumes Acceleron Pharma at Outperform,2016-02-01 08:14:00-05:00,XLRN,neutral
1387089.0,Oppenheimer Assumes Acceleron Pharma at Outperform,2016-02-01 08:14:00-05:00,XLRN,neutral
1387090.0,The Street Might Be Discounting A Potential Blockbuster Drug From Acceleron,2016-01-21 07:35:00-05:00,XLRN,positive
1387091.0,"Credit Suisse Initiates Coverage on Acceleron Pharma at Outperform, Announces $50.00 PT",2016-01-20 16:46:00-05:00,XLRN,positive
1387092.0,13D Filing Shows Acceleron Pharma Sells 800K Shares To Celgene,2016-01-11 16:22:00-05:00,XLRN,positive
1387093.0,Acceleron Prices 3.75M Share Offering @$40.00/Share,2016-01-05 20:04:00-05:00,XLRN,positive
1387094.0,Acceleron Reports Offering of $150M in Common Shares,2016-01-04 17:03:00-05:00,XLRN,positive
1387095.0,Filing from Acceleron Pharma Shows Registration for $300M Common Stock Offering,2016-01-04 16:31:00-05:00,XLRN,neutral
1387096.0,Adam Feuerstein @adamfeuerstein Tweet $XLRN only positive data I saw at #ASH15,2015-12-09 15:34:00-05:00,XLRN,positive
1387097.0,"Celgene, Acceleron Offer New Results from Study with Luspatercept in Beta-Thalassemia at ASH",2015-12-07 17:01:00-05:00,XLRN,neutral
1387098.0,FDA Fast Track Designation Granted to Luspatercept for the Treatment of Patients with Lower-Risk Myelodysplastic Syndromes,2015-12-07 07:00:00-05:00,XLRN,positive
1387099.0,"Celgene, Acceleron Announce New Results from Study with Luspatercept in Myelodysplastic Syndromes Presented at #ASH2015",2015-12-05 13:03:00-05:00,XLRN,neutral
1387100.0,Acceleron Reports Oral Plenary Presentation for ACE-083 in Late-Breaking Trial,2015-12-01 07:03:00-05:00,XLRN,neutral
1387101.0,Benzinga's Top Initiations,2015-11-20 09:42:00-05:00,XLRN,positive
1387102.0,Oppenheimer Initiates Coverage on Acceleron Pharma at Outperform,2015-11-20 07:36:00-05:00,XLRN,neutral
1387103.0,Acceleron Pharma Reports Q3 Loss of $0.36/Share vs Loss of $0.46/Share Est.,2015-11-04 07:08:00-05:00,XLRN,negative
1387104.0,"Acceleron Highlights Phase 3 Studies, New Clinical Results and Research Strategies at Research and Development Day Event",2015-10-23 12:14:00-04:00,XLRN,neutral
1387105.0,"Leerink Chats With Biotech Management, Names 20 Stocks To Buy Now",2015-10-06 14:08:00-04:00,XLRN,neutral
1387106.0,Acceleron Presents Preclinical Data for ACE-083 and ACE-2494 at the 20th International Annual Congress of the World Muscle Society,2015-10-01 07:30:00-04:00,XLRN,neutral
1387107.0,"Acceleron Pharma 13D Shows Holder Polaris Holds 4.5% Stake As Of Aug. 17, Now Holds 1.454M Shares Down From 1.887M Shares",2015-08-27 06:12:00-04:00,XLRN,positive
1387108.0,"Morgan Stanley Initiates Coverage on Acceleron Pharma at Overweight, Announces $50.00 PT",2015-08-13 04:39:00-04:00,XLRN,negative
1387109.0,"Acceleron Pharma Reports Q2 EPS $(0.32) vs. Est. $(0.49), Rev. $5.717M vs. Est. $4.23M",2015-08-06 07:24:00-04:00,XLRN,neutral
1387110.0,JMP Sees A 'Negative Market Tone' In Biotechnology,2015-06-15 13:31:00-04:00,XLRN,negative
1387111.0,Acceleron Reports Publication in Cancer Research Dalantercept Prevents Metastases in Preclinical Studies of Breast Cancer,2015-06-15 07:03:00-04:00,XLRN,negative
1387112.0,Acceleron Announces New Luspatercept Phase 2 Clinical Results at the 20th Congress of the European Hematology Association,2015-06-12 07:00:00-04:00,XLRN,neutral
1387113.0,Watch How These 10 Stocks Respond Today,2015-06-10 08:22:00-04:00,XLRN,neutral
1387114.0,Guggenheim Securities Initiates Coverage on Acceleron Pharma at Neutral,2015-06-09 08:57:00-04:00,XLRN,positive
1387115.0,"Celgene, Acceleron Pharma Announces FDA Fast Track Designation for Luspatercept for Treatment of Patients with Beta-Thalassemia",2015-05-18 07:31:00-04:00,XLRN,neutral
1387116.0,"Acceleron Pharma. Reports Q1 EPS $(0.45) vs. Est. $(0.45), Rev. $4.420M vs. Est. $4.27M",2015-05-07 07:13:00-04:00,XLRN,neutral
1387117.0,"Acceleron Pharma Appoints Steven Ertel EVP, COO and Matthew Sherman M.D. Promoted To EVP, Chief Medical Officer",2015-03-06 08:09:00-05:00,XLRN,positive
1387118.0,Acceleron Pharma Reports Q4 EPS -$0.55 Vs Est. -$0.23,2015-03-02 07:07:00-05:00,XLRN,neutral
1387119.0,Why JMP Securities Is Watching (And Loving) These 3 Biotech Stocks,2015-02-24 16:42:00-05:00,XLRN,positive
1387120.0,19 Lesser-Known Biotech Stocks With Robust Drug Pipelines,2014-12-31 08:59:00-05:00,XLRN,positive
1387121.0,Mid-Afternoon Market Update: Dow Slides Over 100 Points; Oil Futures Down 4%,2014-12-08 15:37:00-05:00,XLRN,neutral
1387122.0,"Celgene, Acceleron Pharma Report Prelim. Data from Ongoing Phase 2 Trials in Patients with Lower Risk MDS:: Luspatercept, Sotatercept Increased Hemoglobin Levels",2014-12-08 14:04:00-05:00,XLRN,negative
1387123.0,"Mid-Day Gainers From December 8: Cubist Pharmaceuticals, Acceleron Pharma, Calithera Biosciences, Cempra, Isis Pharmaceuticals",2014-12-08 13:00:00-05:00,XLRN,neutral
1387124.0,Mid-Day Market Update: McDonald's Drops On Weak November Sales; Acceleron Pharma Shares Jump,2014-12-08 12:56:00-05:00,XLRN,negative
1387125.0,Mid-Morning Market Update: Markets Mixed; Merck To Buy Cubist Pharmaceuticals For $102/Share,2014-12-08 10:46:00-05:00,XLRN,neutral
1387126.0,Stocks Hitting 52-Week Highs,2014-12-08 10:08:00-05:00,XLRN,neutral
1387127.0,Morning Market Movers,2014-12-08 09:44:00-05:00,XLRN,neutral
1387128.0,Benzinga's Top #PreMarket Gainers,2014-12-08 08:11:00-05:00,XLRN,positive
1387129.0,"Celgene, Acceleron Present New Data from Luspatercept Phase 2 Clinical Trial in Beta-Thalassemia at ASH Annual Meeting",2014-12-07 16:21:00-05:00,XLRN,neutral
1387130.0,Acceleron Pharma Inc. Announces Sotatercept Data from the Phase 2a Clinical Trial in Hemodialysis Patients Presented at the American Society of Nephrology Kidney Week 2014,2014-11-13 09:31:00-05:00,XLRN,neutral
1387131.0,Acceleron Reports Q3 EPS of $(0.25) vs $(0.42) Est,2014-11-07 07:33:00-05:00,XLRN,neutral
1387132.0,Acceleron Initiates Phase 1 Clinical Trial With Innovative Muscle Drug ACE-083,2014-10-14 07:30:00-04:00,XLRN,positive
1387133.0,Acceleron Offers Update on Externally-Sponsored Clinical Trial of Dalantercept Monotherapy in Ovarian Cancer,2014-09-23 08:33:00-04:00,XLRN,negative
1387134.0,"FBR Capital Initiates Coverage on Acceleron at Outperform, Announces $47.00 PT",2014-08-14 06:26:00-04:00,XLRN,neutral
1387135.0,"Leerink Swann Initiates Coverage on Acceleron at Outperform, Announces $57.00 PT",2014-08-14 06:26:00-04:00,XLRN,neutral
1387136.0,Acceleron Reports Q2 EPS of $(0.52) vs $(0.45) Est,2014-08-12 07:03:00-04:00,XLRN,neutral
1387137.0,"Events Scheduled for Week of Jun 23rd to Jun 27th, 2014",2014-06-23 18:25:00-04:00,XLRN,neutral
1387138.0,Acceleron Reports Q1 EPS of $(0.30) vs $(0.44) Est; Revenue of $3.31M vs $2.85M Est,2014-05-15 07:31:00-04:00,XLRN,neutral
1387139.0,Acceleron To Report Encouraging Clinical Data From Phase 2 Dalantercept at American Society of Oncology June 2,2014-05-14 17:01:00-04:00,XLRN,positive
1387140.0,Mid-Day Market Update: Apollo Drops After Q2 Results; MannKind Shares Spike Higher,2014-04-02 12:31:00-04:00,XLRN,positive
1387141.0,Mid-Morning Market Update: Markets Flat; Monsanto Earnings Beat Street View,2014-04-02 10:38:00-04:00,XLRN,neutral
1387142.0,Morning Market Movers,2014-04-02 09:40:00-04:00,XLRN,neutral
1387143.0,Form 8-K Acceleron Pharma Shows Celgene to Buy 1.1M Shares for $47.15M,2014-04-02 08:02:00-04:00,XLRN,positive
1387144.0,"Acceleron Pharma Announces Closing of Offering, Reports Full Exercise of Overallotment Options by Underwriters, Expecting Proceeds of ~$129M",2014-01-28 16:33:00-05:00,XLRN,neutral
1387145.0,Benzinga's Top #PreMarket Losers,2014-01-23 08:17:00-05:00,XLRN,negative
1387146.0,Acceleron Prices 2.4M Share Offering at $50.00/Share,2014-01-22 22:49:00-05:00,XLRN,positive
1387147.0,US Stock Futures Signal Higher Start On Wall Street,2014-01-21 06:56:00-05:00,XLRN,neutral
1387148.0,Acceleron Commences $100M Offering of Common Stock ,2014-01-21 06:33:00-05:00,XLRN,neutral
1387149.0,15 Notable IPOs of 2013: Investment Idea of the Day,2014-01-03 09:45:00-05:00,XLRN,neutral
1387150.0,Acceleron Earns $7M Milestone Payment f Celgene,2013-12-18 07:07:00-05:00,XLRN,neutral
1387151.0,UPDATE: JMP Securities Reiterates on Acceleron Pharma on Elevated Confidence,2013-12-12 12:12:00-05:00,XLRN,positive
1387152.0,"JMP Securities Maintains Market Outperform on Acceleron, Raises PT to $36.00",2013-12-12 07:02:00-05:00,XLRN,positive
1387153.0,"Acceleron, Celgene Report New Interim Clinical Data from Phase 2 Trial of Sotatercept in Beta-Thalassemia at ASH",2013-12-09 11:02:00-05:00,XLRN,neutral
1387154.0,Acceleron Announces Presentation of New Interim Phase 2 Sotatercept Clinical Data in Beta-Thalassemia ,2013-12-02 07:09:00-05:00,XLRN,neutral
1387155.0,Acceleron Reports Q3 EPS of $(5.62) Which May Not Compare $(0.40) Est,2013-11-06 07:02:00-05:00,XLRN,neutral
1387156.0,UPDATE: Piper Jaffray Initiates Coverage on Acceleron Pharma on Promising Anemia and Cancer Play,2013-10-14 09:15:00-04:00,XLRN,negative
1387157.0,Benzinga's Top Initiations,2013-10-14 07:59:00-04:00,XLRN,positive
1387158.0,"Citigroup Initiates Coverage on Acceleron at Buy, Announces $30.00 PT",2013-10-14 07:45:00-04:00,XLRN,neutral
1387159.0,"Leerink Swann Initiates Coverage on Acceleron at Outperform, Announces $33.00 PT",2013-10-14 07:25:00-04:00,XLRN,neutral
1387160.0,"JMP Securities Initiates Coverage on Acceleron at Market Outperform, Announces $32.00 PT",2013-10-14 07:25:00-04:00,XLRN,positive
1387161.0,"Piper Jaffray Initiates Coverage on Acceleron at Overweight, Announces $32.00 PT",2013-10-14 06:27:00-04:00,XLRN,negative
1387162.0,"Shares of Acceleron Pharma Open at $18.50 After Pricing at $15, Stock Now Up to $19.35",2013-09-19 10:54:00-04:00,XLRN,positive
1387163.0,"IPO for Acceleron Pharma to Open for Trade at 10:40AM EDT, Quotes Opened as of 10:25AM; Co. Priced 5.58M Shares at $15/Share",2013-09-19 10:28:00-04:00,XLRN,positive
1387164.0,Acceleron Prices 5.58M Share IPO at $15.00/Share,2013-09-18 21:12:00-04:00,XLRN,positive
